Updated NETs Clinical Trials

1. Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors

   Condition:   Neuroendocrine Tumors
   Intervention:   Radiation: MIBG-I131
   Sponsor:   AC Camargo Cancer Center
   Recruiting

2. A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors

   Condition:   Neuroendocrine Tumors
   Intervention:   Drug: 64Cu-SARTATE
   Sponsor:   Clarity Pharmaceuticals Ltd
   Recruiting

3. 68Ga-DOTA-TATE PET/CT Imaging in NETs

   Condition:   Neuroendocrine Tumors
   Intervention:   Diagnostic Test: 68Ga-DOTA-TATE
   Sponsors:   Centre de recherche du Centre hospitalier universitaire de Sherbrooke;   Université de Sherbrooke
   Recruiting

4. Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

   Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
   Interventions:   Drug: Olaparib;   Drug: Durvalumab
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

5. Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

   Condition:   Neuroendocrine Carcinoma
   Interventions:   Drug: FOLFOXIRI Protocol;   Drug: Cisplatin injection
   Sponsors:   Centre Hospitalier Universitaire Dijon;   National Cancer Institute, France
   Recruiting

6. Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

   Conditions:   Metastatic Large Cell Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Carcinoma;   Metastatic Neuroendocrine Neoplasm;   Metastatic Small Cell Neuroendocrine Carcinoma
   Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
   Sponsor:   National Cancer Institute (NCI)
   Recruiting

7. Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

   Conditions:   Neuroendocrine Tumors;   Carcinoid Syndrome;   Diarrhea
   Interventions:   Drug: Telotristat ethyl;   Drug: Peptide Receptor Radionuclide Therapy;   Other: Placebo
   Sponsors:   Pashtoon Kasi, MD, MS;   TerSera Therapeutics LLC
   Recruiting

8. Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer [PLANE-PC]

   Conditions:   Prostate Cancer Metastatic;   Neuroendocrine Tumors
   Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib
   Sponsors:   Ulka Vaishampayan;   Merck Sharp & Dohme Corp.;   University of Michigan
   Not yet recruiting

9. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

   Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
   Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
   Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Ipsen
   Recruiting

10. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

    Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

11. Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

    Condition:   Neuroendocrine Tumors
    Interventions:   Drug: 177Lu-edotreotide PRRT;   Drug: Everolimus;   Other: Amino-Acid Solution
    Sponsors:   ITM Solucin GmbH;   ABX CRO;   PSI CRO AG
    Recruiting

12. A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

    Condition:   Carcinoma, Neuroendocrine
    Intervention:   Drug: [177]Lu-DOTA-TATE
    Sponsor:   AHS Cancer Control Alberta
    Recruiting

13. Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

    Conditions:   Lung Small Cell Carcinoma;   Neuroendocrine Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Dostarlimab;   Drug: Niraparib
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

14. Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

    Conditions:   Locally Advanced Well Differentiated Neuroendocrine Neoplasm;   Metastatic Well Differentiated Neuroendocrine Neoplasm
    Interventions:   Drug: Placebo Administration;   Other: Questionnaire Administration;   Drug: Telotristat Ethyl
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting

15. Open-Label Surufatinib in European Patients With NET

    Conditions:   Neuroendocrine Tumours;   Neuroendocrine Tumour of the Lung;   Small Intestinal NET
    Intervention:   Drug: Surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Not yet recruiting

16. Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

    Conditions:   Neuroendocrine Tumor;   Liver Metastases;   Neuroendocrine Gastroenteropancreatic Tumour
    Interventions:   Procedure: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection;   Procedure: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection;   Drug: LUTATHERA® by intra-arterial hepatic (IAH) injection;   Procedure: Scan
    Sponsors:   University Hospital, Bordeaux;   Advanced Accelerator Applications
    Not yet recruiting

17. A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

    Conditions:   Gastro-enteropancreatic Neuroendocrine Tumor;   Neuroendocrine Tumors
    Interventions:   Drug: Lutathera;   Drug: Azedra
    Sponsors:   David Bushnell;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Progenics Pharmaceuticals, Inc.
    Not yet recruiting

18. Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

    Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

19. Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

    Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

20. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

    Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

21. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

    Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
    Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
    Sponsor:   Advanced Accelerator Applications
    Recruiting

22. Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

    Conditions:   Gastric Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Sarcoma;   Mesothelioma;   Neuroendocrine Tumors;   Squamous Cell Cancer;   Merkel Cell Carcinoma;   Mismatch Repair Deficiency;   Microsatellite Instability
    Interventions:   Biological: Tumor Infiltrating Lymphocytes (TIL);   Drug: Fludarabine + Cyclophosphamide combination
    Sponsor:   Udai Kammula
    Recruiting

23. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

    Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Breast Metaplastic Carcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Solid Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

24. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

    Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

25. Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery

    Conditions:   Surgery;   Analgesia
    Interventions:   Drug: Liposomal bupivacaine;   Other: Thoracic epidural analgesia (bupivacaine)
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Pacira Pharmaceuticals, Inc
    Not yet recruiting

26. A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

    Condition:   Tumors
    Intervention:   Drug: surufatinib
    Sponsor:   Hutchison Medipharma Limited
    Recruiting

27. Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

    Conditions:   Bladder Small Cell Neuroendocrine Carcinoma;   Extensive Stage Lung Small Cell Carcinoma;   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Limited Stage Lung Small Cell Carcinoma;   Platinum-Resistant Lung Small Cell Carcinoma;   Platinum-Sensitive Lung Small Cell Carcinoma;   Prostate Small Cell Neuroendocrine Carcinoma;   Recurrent Lung Small Cell Carcinoma
    Interventions:   Drug: Berzosertib;   Drug: Topotecan Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

28. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

29. A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

    Condition:   Covid19
    Interventions:   Drug: Inhaled Aviptadil;   Drug: Placebo
    Sponsors:   Centurion Pharma;   Klinar CRO
    Recruiting

30. Estrogen Administration for the Treatment of NASH in Postmenopausal Women

    Condition:   NASH - Nonalcoholic Steatohepatitis
    Interventions:   Drug: Estradiol patch;   Drug: Placebo
    Sponsor:   Massachusetts General Hospital
    Not yet recruiting

31. Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

    Conditions:   Appendix Carcinoma;   Colon Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Malignant Digestive System Neoplasm;   Pancreatic Carcinoma;   Rectal Carcinoma;   Small Intestinal Carcinoma;   Anal Carcinoma;   Digestive System Carcinoma;   Digestive System Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor
    Interventions:   Procedure: Acupuncture Therapy;   Procedure: Acupressure Therapy;   Procedure: Oral Cryotherapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   The Safeway Foundation
    Recruiting

32. Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

    Conditions:   Metastatic Solid Tumor;   Colorectal Cancer;   Neuroendocrine Tumors;   Small Cell Lung Cancer;   Gastric Cancer;   Soft Tissue Sarcoma
    Interventions:   Drug: Surufatinib and Tislelizumab _ Part 1;   Drug: Surufatinib and Tislelizumab _ Part 2
    Sponsors:   Hutchison Medipharma Limited;   BeiGene
    Recruiting

33. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

34. Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

    Conditions:   Motor Function;   Cognitive Function;   Contrast Media
    Interventions:   Procedure: Motor Tests;   Procedure: Cognitive Tests;   Procedure: Unenhanced-MRI of the brain;   Procedure: Gadolinium Measurements;   Drug: Gadoxetate disodium;   Drug: Gadobenate dimeglumine;   Drug: Gadodiamide;   Drug: Gadoterate meglumine;   Drug: Gadobutrol;   Drug: Gadoteridol
    Sponsors:   Guerbet;   Bayer AG (Sponsor);   Bracco (Sponsor);   GEHC (Sponsor)
    Recruiting

35. A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

    Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting

36. Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

    Condition:   Breast Cancer
    Interventions:   Drug: alpelisib;   Drug: fulvestrant;   Drug: letrozole;   Drug: Goserelin;   Drug: Leuprolide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

37. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

    Conditions:   Locally Advanced Thyroid Gland Carcinoma;   Malignant Thyroid Gland Neoplasm;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Anaplastic Carcinoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Papillary Carcinoma;   Thyroid Gland Squamous Cell Carcinoma
    Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Selpercatinib;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

38. Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study

    Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

39. Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer, STAMP Study

    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

40. Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

41. Nimodipine in Vestibular Schwanommas

    Condition:   Vestibular Schwannoma
    Interventions:   Drug: NiMODipine Injectable Solution;   Other: Placebo
    Sponsor:   Medical University of Vienna
    Not yet recruiting

42. Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

    Conditions:   Viral Pneumonia;   Serotonin Syndrome;   Platelet Dysfunction
    Intervention:   Drug: Cyproheptadine Hydrochloride 4 MG
    Sponsors:   Ciusss de L'Est de l'Île de Montréal;   Covid-19 Early Treatment Fund
    Not yet recruiting